Several meta-analyses have recently been published on SGLT2 inhibitors for primary and secondary prevention of cardiovascular outcomes in T2D with an attempt to reconcile what patient characteristics (e.g. presence/absence of atherosclerotic cardiovascular disease (ASCVD), history of HF or baseline renal function) will derive cardiorenal protection [38,39]. This evidence concerns the gene SLC5A2 and hydrops fetalis.